Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 7/20 | 0.80 |
| ▸ | KDR | P35968 | 6/20 | 0.80 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.65 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.62 |
| ▸ | MET | P08581 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7481946 | 0.92 | PDGFRA (0.76) | PDGFRAKDRPDGFRBFGFR2MET | |
| SCHEMBL1893582 | 0.90 | PDGFRA (0.70) | PDGFRAKDRPDGFRBFGFR2MET | |
| SCHEMBL7489788 | 0.89 | PDGFRA (1.00) | PDGFRAKDR | |
| SCHEMBL1895559 | 0.88 | PDGFRA (0.65) | PDGFRAKDRPDGFRBFGFR2MET | |
| SCHEMBL1875065 | 0.87 | PDGFRA (0.92) | PDGFRAKDRMET | |
| SCHEMBL8556030 | 0.87 | PDGFRA (0.69) | PDGFRAKDRPDGFRBFGFR2MET | |
| SCHEMBL1889615 | 0.87 | PDGFRA (0.64) | PDGFRAKDRPDGFRBFGFR2MET | |
| SCHEMBL21200800 | 0.87 | KDR (0.70) | PDGFRAKDRPDGFRBFGFR2MET | |
| SCHEMBL12410619 | 0.87 | PDGFRA (0.64) | PDGFRAKDRPDGFRBFGFR2MET | |
| SCHEMBL12411170 | 0.87 | PDGFRA (0.64) | PDGFRAKDRPDGFRBFGFR2MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103664778-A | Synthesis method of antineoplastic drug cabozant inib | SUZHOU MOLE PHARMACEUTICAL CO LTD | 2014-03-26 | — | — | CN | claimed |
| CN-121226242-A | Synthetic cabozite method for preparing nylon intermediate | 鲁南制药集团股份有限公司 | 2025-12-30 | — | — | CN | disclosed |
| CN-121226243-A | Cabozitinib medium Process for the preparation of intermediates | 鲁南制药集团股份有限公司 | 2025-12-30 | — | — | CN | disclosed |
| US-20250243165-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | EXELIXIS INC (US) | 2025-07-31 | — | — | US | disclosed |
| WO-2025125873-A1 | PROCEDURE FOR THE PURIFICATION OF CABOZANTINIB | STERLING CHEMICAL MALTA LTD. (MT) | 2025-06-19 | — | — | WO | disclosed |
| US-12275706-B2 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | EXELIXIS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20250084037-A1 | MALATE SALT OF N-(4-{[6,7-BIS(METHYLOXY) QUINOLIN-4-YL]OXY}PHENYL)-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE, AND CRYSTALLINE FORMS THEREOF FOR THE TREATMENT OF CANCER | PHARMORPHIX (GB) | 2025-03-13 | — | — | US | disclosed |
| US-20240316030-A1 | METHOD OF TREATING CANCER AND BONE CANCER PAIN | EXELIXIS INC (US) | 2024-09-26 | — | — | US | disclosed |
| US-20240279181-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | EXELIXIS INC (US) | 2024-08-22 | — | — | US | disclosed |
| US-20240156803-A1 | Method of Treating Cancer | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-05-16 | — | — | US | disclosed |
| EP-2023926-A1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | Bayer HealthCare AG (DE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008048375-A1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | BAYER HEALTHCARE AG (DE) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008048375-A1 | PYRIDONECARBOXAMIDE DERIVATIVES USEFUL IN TREATING HYPER-PROLIFERATIVE AND ANGIOGENESIS DISORDERS | BAYER HEALTHCARE AG (DE) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008035209-A2 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2008-03-27 | — | — | WO | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| EP-0860433-B1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF GROWTH FACTOR RECEPTOR ORIGINATING IN PLATELET AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | KIRIN BREWERY (JP) | 2002-07-03 | — | — | EP | disclosed |
| US-6143764-A | ETHER DERIVATIVES OF QUINOLINE, ANTITUMOR AGENTS | KIRIN BEER KABUSHIKI KAISHA (JP) | 2000-11-07 | — | — | US | disclosed |
| EP-0860433-A1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF GROWTH FACTOR RECEPTOR ORIGINATING IN PLATELET AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 1998-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156803-A1 | Method of Treating Cancer | MET, HGF, ACP3 | PDGFRA 109/4885KDR 8/4885PDGFRB 70/4885 |
| US-20250243165-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | MDH1, MDH2, ME1 | PDGFRA 2690/4885KDR 4344/4885PDGFRB 4141/4885 |
| US-20240316030-A1 | METHOD OF TREATING CANCER AND BONE CANCER PAIN | TPO, OGFR, CALCR | PDGFRA 2352/4885KDR 2332/4885PDGFRB 2385/4885 |
| US-20240279181-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | MDH1, MDH2, ME1 | PDGFRA 2690/4885KDR 4344/4885PDGFRB 4141/4885 |
| US-12275706-B2 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | MDH1, MDH2, SLC25A11 | PDGFRA 3001/4885KDR 4270/4885PDGFRB 4203/4885 |
| US-20250084037-A1 | MALATE SALT OF N-(4-{[6,7-BIS(METHYLOXY) QUINOLIN-4-YL]OXY}PHENYL)-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE, AND CRYSTALLINE FORMS THEREOF FOR THE TREATMENT OF CANCER | MDH1, MDH2, SLC25A11 | PDGFRA 3033/4885KDR 4284/4885PDGFRB 4216/4885 |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | HGF, ERBB2, MET | PDGFRA 26/4885KDR 11/4885PDGFRB 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.